GB0611552D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB0611552D0
GB0611552D0 GBGB0611552.1A GB0611552A GB0611552D0 GB 0611552 D0 GB0611552 D0 GB 0611552D0 GB 0611552 A GB0611552 A GB 0611552A GB 0611552 D0 GB0611552 D0 GB 0611552D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0611552.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0611552.1A priority Critical patent/GB0611552D0/en
Publication of GB0611552D0 publication Critical patent/GB0611552D0/en
Priority to TW096120008A priority patent/TW200815378A/en
Priority to KR1020087030959A priority patent/KR20090015980A/en
Priority to PCT/GB2007/002097 priority patent/WO2007144571A1/en
Priority to CA002653550A priority patent/CA2653550A1/en
Priority to MX2008015762A priority patent/MX2008015762A/en
Priority to CNA2007800217295A priority patent/CN101466690A/en
Priority to AU2007259031A priority patent/AU2007259031A1/en
Priority to BRPI0712354-0A priority patent/BRPI0712354A2/en
Priority to EP07733109A priority patent/EP2041101A1/en
Priority to JP2009514875A priority patent/JP2009539954A/en
Priority to ARP070102537A priority patent/AR061332A1/en
Priority to UY30404A priority patent/UY30404A1/en
Priority to CL2007001700A priority patent/CL2007001700A1/en
Priority to IL195348A priority patent/IL195348A0/en
Priority to NO20084963A priority patent/NO20084963L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
GBGB0611552.1A 2006-06-12 2006-06-12 Chemical compounds Ceased GB0611552D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0611552.1A GB0611552D0 (en) 2006-06-12 2006-06-12 Chemical compounds
TW096120008A TW200815378A (en) 2006-06-12 2007-06-04 Chemical compound
JP2009514875A JP2009539954A (en) 2006-06-12 2007-06-08 Crystals of (trans-4- {4-[({5-[(3,4-difluorophenyl) amino] -1,3,4-oxadiazol-2-yl} carbonyl) amino] phenyl} cyclohexyl) acetic acid form
CNA2007800217295A CN101466690A (en) 2006-06-12 2007-06-08 Crystalline forms of (trans-4-[({5-[(3, 4-difluorophenyl) amino]-1,3, 4-oxadiazol-2-yl} carbonyl) amino] phenyl) cyclohexyl) acetic acid
EP07733109A EP2041101A1 (en) 2006-06-12 2007-06-08 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino]-1,3, 4-oxadiazol-2-yl}carbonyl) amino]ph enyl } cyclohexyl) acetic acid
CA002653550A CA2653550A1 (en) 2006-06-12 2007-06-08 Crystalline form of (trans-4- [( { 5-[(3,4-difluorophenyl) amino]-1,3,4-oxadiazol-2-yl}carbonyl)amino]phenyl}cyclohexyl) acetic acid
MX2008015762A MX2008015762A (en) 2006-06-12 2007-06-08 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino] -1,3, 4-oxadiazol-2-yl}carbonyl) amino] ph enyl } cyclohexyl) acetic acid.
KR1020087030959A KR20090015980A (en) 2006-06-12 2007-06-08 Crystalline form of (trans-4-[([5-[(3,4-difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl)amino]phenyl]cyclohexyl)acetic acid
AU2007259031A AU2007259031A1 (en) 2006-06-12 2007-06-08 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino] -1,3, 4-oxadiazol-2-yl}carbonyl) amino) phenyl } cyclohexyl) acetic acid
BRPI0712354-0A BRPI0712354A2 (en) 2006-06-12 2007-06-08 crystalline form of a compound, pharmaceutical formulation, use of the compound, and method of treating a condition.
PCT/GB2007/002097 WO2007144571A1 (en) 2006-06-12 2007-06-08 Crystalline form of (trans-4- [ ( { 5- [ (3, 4 -di fluorophenyl) amino] -1,3, 4-oxadiazol-2-yl}carbonyl) amino] ph enyl } cyclohexyl) acetic acid
CL2007001700A CL2007001700A1 (en) 2006-06-12 2007-06-11 Crystalline forms 2 and 3 of the acid (trans-4- {4 - ((5- (3,4-difluorophenyl) amino} -1,3,4-oxadiazol-2-yl) carbonyl) amino} phenyl) cyclohexyl) acetic ; pharmaceutical composition comprising said compound; and its use to inhibit the activity of diacylglycerol acyltransferase (dgat1)
ARP070102537A AR061332A1 (en) 2006-06-12 2007-06-11 OXADIAZOL COMPOUND AS INHIBITOR OF DGAT1 (DIACILGLICEROL ACILTRANSFERASA)
UY30404A UY30404A1 (en) 2006-06-12 2007-06-11 NEW CRYSTAL FORMS OF ACID (TRANS-4- {4 - [({5 - [(3,4-DIFLUOROPHENYL) AMINO] -1,3,4-OXADIAZOL-2-IL} CARBONYL) AMINO] PHENYL} CILOHEXIL) ACETIC , COMPOSITIONS AND APPLICATIONS
IL195348A IL195348A0 (en) 2006-06-12 2008-11-17 Crystalline form of (trans-4-[({5-[(3,4-difluorophenyl)amino]-1,3,4-oxadiazol-2-yl}carbonyl)amino]phenyl}cyclohexyl)acetic acid
NO20084963A NO20084963L (en) 2006-06-12 2008-11-26 Crystalline forms of (trans-4 - [({5- [3,4-difluorophenyl) amino] -1,3,4-oxadiazol-2-yl} carbonyl) amino] phenyl} cyclohexyl) acetic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0611552.1A GB0611552D0 (en) 2006-06-12 2006-06-12 Chemical compounds

Publications (1)

Publication Number Publication Date
GB0611552D0 true GB0611552D0 (en) 2006-07-19

Family

ID=36745696

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0611552.1A Ceased GB0611552D0 (en) 2006-06-12 2006-06-12 Chemical compounds

Country Status (16)

Country Link
EP (1) EP2041101A1 (en)
JP (1) JP2009539954A (en)
KR (1) KR20090015980A (en)
CN (1) CN101466690A (en)
AR (1) AR061332A1 (en)
AU (1) AU2007259031A1 (en)
BR (1) BRPI0712354A2 (en)
CA (1) CA2653550A1 (en)
CL (1) CL2007001700A1 (en)
GB (1) GB0611552D0 (en)
IL (1) IL195348A0 (en)
MX (1) MX2008015762A (en)
NO (1) NO20084963L (en)
TW (1) TW200815378A (en)
UY (1) UY30404A1 (en)
WO (1) WO2007144571A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007101A (en) 2004-12-14 2007-08-21 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors.
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
CN101415683B (en) 2006-03-31 2013-07-17 诺瓦提斯公司 New compounds
KR20090012349A (en) 2006-05-30 2009-02-03 아스트라제네카 아베 Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
BRPI0712796A2 (en) 2006-05-30 2012-10-02 Astrazeneca Ab compound, methods for producing an inhibition of dgat1 activity in a warm-blooded animal, for treating diabetes mellitus and / or obesity in a warm-blooded animal, use of a compound, pharmaceutical composition, and process for a compound
US20100093733A1 (en) * 2007-02-15 2010-04-15 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
AR066169A1 (en) 2007-09-28 2009-07-29 Novartis Ag DERIVATIVES OF BENZO-IMIDAZOLES, USEFUL FOR DISORDERS ASSOCIATED WITH THE ACTIVITY OF DGAT
PE20091682A1 (en) 2007-12-20 2009-12-04 Astrazeneca Ab CARBAMOYL COMPOUNDS AS INHIBITORS OF DGAT1 190
EP2408774B1 (en) 2009-03-20 2014-11-26 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
EP2443096A1 (en) 2009-06-19 2012-04-25 AstraZeneca AB Pyrazine carboxamides as inhibitors of dgat1
FR2963005B1 (en) * 2010-07-23 2012-08-17 Sanofi Aventis DERIVATIVES OF OXADIAZOLES AND PYRIDAZINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044152A1 (en) * 2003-05-09 2005-08-24 Bayer Corp RENTAL DERIVATIVES, METHOD OF PREPARATION AND USE FOR THE TREATMENT OF OBESITY
MX2007007101A (en) * 2004-12-14 2007-08-21 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors.

Also Published As

Publication number Publication date
NO20084963L (en) 2009-01-07
AU2007259031A1 (en) 2007-12-21
UY30404A1 (en) 2008-01-31
AR061332A1 (en) 2008-08-20
KR20090015980A (en) 2009-02-12
IL195348A0 (en) 2009-08-03
MX2008015762A (en) 2009-03-16
EP2041101A1 (en) 2009-04-01
JP2009539954A (en) 2009-11-19
BRPI0712354A2 (en) 2012-06-05
WO2007144571A1 (en) 2007-12-21
CL2007001700A1 (en) 2008-01-18
CA2653550A1 (en) 2007-12-21
CN101466690A (en) 2009-06-24
TW200815378A (en) 2008-04-01

Similar Documents

Publication Publication Date Title
EP1984376A4 (en) Chemical compounds
IL192661A0 (en) Chemical compounds
IL196595A0 (en) Chemical compounds
GB0619342D0 (en) New chemical compounds
EP2136632A4 (en) Chemical compounds
GB0713117D0 (en) Chemical compounds
EP2136635A4 (en) Chemical compounds
EP2166856A4 (en) Chemical compounds
GB0611507D0 (en) Chemical compounds
GB0611506D0 (en) Chemical compounds
GB0623388D0 (en) Chemical compounds
GB0702384D0 (en) Chemical compounds
GB0611552D0 (en) Chemical compounds
GB0707662D0 (en) Chemical compounds
GB0619343D0 (en) New chemical compounds
ZA200903100B (en) Chemical compounds
GB0625198D0 (en) Chemical compounds
GB0601215D0 (en) Chemical compounds
GB0623357D0 (en) Chemical compounds
GB0615670D0 (en) Chemical compounds
GB0614552D0 (en) Chemical Compounds
GB0625371D0 (en) Chemical compounds
GB0617868D0 (en) Chemical compounds
GB0600510D0 (en) Chemical compounds
GB0612116D0 (en) Chemical Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)